Corpus Intelligence IC Memo — RAMAPO RIDGE PSYCHIATRIC 2026-04-26 08:03 UTC
IC Memo — RAMAPO RIDGE PSYCHIATRIC
Investment Committee Memorandum | NJ | 58 beds | Grade C | EBITDA uplift $5.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RAMAPO RIDGE PSYCHIATRIC

CCN 314019 | BERGEN, NJ | 58 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RAMAPO RIDGE PSYCHIATRIC is a 58-bed under-performing / distressed in BERGEN, NJ with $78.4M in net patient revenue and a -34.4% operating margin. The hospital serves a payer mix of 51.9% Medicare, 13.5% Medicaid, and 34.7% commercial.

Thesis: Turnaround. Our ML models identify $5.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -34.4% to -27.0% (+736bps).

Net Revenue HCRIS$78.4M
Current EBITDA COMPUTED$-27.0M
Operating Margin COMPUTED-34.4%
Occupancy HCRIS71.5%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS76.0%
Distress Probability ML51.3%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
29
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of -34.4% places it below the state median. Among 29 size-comparable peers (29-116 beds), the median margin is -3.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (29-116), prioritizing same-state peers. 29 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RAMAPO RIDGE PSYCHIATRIC (Target)NJ58$78.4M-34.4%
DEBORAH HEART AND LUNG CENTERNJ85$211.9M-5.5%
ST LUKES WARREN HOSPITALNJ92$200.8M28.1%
BERGEN NEW BRIDGE MEDICAL CENTNJ101$187.0M-39.4%
HUDSON REGIONAL HOSPITALNJ102$152.7M2.4%
CHILDRENS SPECIALIZED HOPSITALNJ68$150.1M-18.1%
HACKENSACK UMC AT PASCACK VALLNJ78$148.8M15.0%
HOBOKEN UNIVERSITY MEDICAL CENNJ114$133.9M-48.9%
HACKETTSTOWN MEDICAL CENTERNJ95$119.6M2.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.6M+210bp18mo
Cost to Collect4.5%2.5%$1.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$954K+122bp9mo
Clean Claim Rate88.0%96.0%$50K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.6M
Cost to Collect
$1.6M
Denial Rate Reduction
$1.6M
A/R Days Reduction
$954K
Clean Claim Rate
$50K
Total EBITDA Uplift$5.8M
Current EBITDA$-27.0M
+ RCM Uplift+$5.8M
Pro Forma EBITDA$-21.2M
Current Margin-34.4%
Pro Forma Margin-27.0%
WC Released (1x)$3.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-41.5M$-120.1M0.00x-100.0%
Base (11x exit)10.0x11.0x$-41.5M$-145.6M0.00x-100.0%
Bull Case9.0x11.0x$-37.3M$-140.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-37.3M$-163.8M0.00x-100.0%
Bear Case11.0x10.0x$-45.6M$-135.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-45.6M$-163.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 51.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 29 hospitals with 29-116 beds
  • Same-state prioritization (n=30)
  • Comp margins: P25=-25.7% / P50=-3.8% / P75=9.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.